HBIO - Harvard Bioscience, Inc.
| Previous Close | 5.87 |
| Open | 5.86 |
| Bid | 5.58 x 900 |
| Ask | 5.58 x 900 |
| Day's Range | 5.46 - 5.89 |
| 52 Week Range | 1.98 - 6.29 |
| Volume | |
| Avg. Volume | 213,588 |
| Market Cap | 234.576M |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Sidoti's Micro-Cap Virtual May Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links.
- GlobeNewswire
Harvard Bioscience to Present at Sidoti Micro Cap Virtual Conference May 10th, 2023
HOLLISTON, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Micro Cap Virtual Conference taking place on May 10th, 2023. Mr. Green will present on Wednesday, May 10th at 11:30 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harvard
- GlobeNewswire
Harvard Bioscience Announces First Quarter 2023 Financial Results
Q1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a loss of $6.7 million prior yearQ1 Adjusted Operating Income of $4.4 million up from $2.4 million prior year HOLLISTON, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the first quarter ended March 31, 2023. First quarter revenues were $30.0 million, up 4% versus $28.8 million in Q1 ‘22. Reported revenue i
- GlobeNewswire
Harvard Bioscience Announces Initial Order for Integrated Animal Behavior Monitoring System
Designed to meet the pre-clinical testing needs of CROs, pharma and research laboratoriesHOLLISTON, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the initial order for the Company’s new high-capacity behavioral monitoring system for pre-clinical applications. This initial order, which was placed by one of the Company’s large contract research organization (CRO) customers, is scheduled for delivery in the fourth quarter of 2023.
- GlobeNewswire
Harvard Bioscience Schedules First Quarter 2023 Earnings Conference Call for April 25, 2023 at 9:00 AM ET
HOLLISTON, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2023 before the market opens on April 25, 2023, and will hold a conference call to discuss the results at 9:00 a.m. Eastern Time. Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who would like to join the audio-
- ACCESSWIRE
Sidoti's Small-Cap Virtual March Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day March Small-Cap Conference taking place Wednesday and Thursday, March 22-23, 2023.
- GlobeNewswire
Harvard Bioscience to Present at Sidoti Investor Conference March 22-23, 2023
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the Sidoti Virtual Investor Conference taking place on March 22-23, 2023. Mr. Green will present on Wednesday, March 22 at 10:00 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of the Harv
- GlobeNewswire
Harvard Bioscience to Present at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023
HOLLISTON, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Chairman and Chief Executive Officer Jim Green will present and host one-on-one meetings with investors at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023. Mr. Green will present on Tuesday, March 21 at 9:45 AM ET. A live webcast of the presentation will be available here. The presentation will also be archived on the Investor Relations section of
- GlobeNewswire
Harvard Bioscience Announces Fourth Quarter 2022 Financial Results
HOLLISTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the fourth quarter and year ended December 31, 2022. Our fourth quarter revenues were $28.4 million, down 14% versus the comparable prior year period, including a negative currency impact of $1.0 million. During the quarter ended December 31, 2022, our cellular and molecular product revenues were roughly flat after adjusting for currency impacts. Pre-
- GlobeNewswire
Harvard Bioscience Schedules Fourth Quarter 2022 Earnings Conference Call for March 9, 2023 at 8:00 AM ET
HOLLISTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for fourth quarter ended December 31, 2022 before the market opens on March 9, 2023, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who want to join the audio-only web
- GlobeNewswire
Harvard Bioscience Announces CFO Transition
HOLLISTON, Mass., Dec. 12, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced the resignation of Michael Rossi, the Company’s chief financial officer and treasurer, effective December 31, 2022. The Company has appointed Jennifer Cote, the Company’s vice president of global finance, as its interim chief financial officer and treasurer, effective upon Mr. Rossi’s resignation. Mr. Rossi will remain with the Company through May 10, 2023 to provide transi
- GlobeNewswire
Harvard Bioscience Announces Third Quarter 2022 Financial Results
“Fighting through challenging times while building the company and new technologies for the future.”HOLLISTON, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter ended September 30, 2022. Jim Green, Chairman and CEO, said, "Impacted by a challenging summer, our third quarter revenues were $26.9 million, down 9% from the same quarter prior year. Growth of 6% in our cellular/molecular product reve
- GlobeNewswire
Harvard Bioscience Schedules Third Quarter 2022 Earnings Conference Call for November 8, 2022 at 4:30 PM ET
HOLLISTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2022 after the market closes on November 8, 2022, and will hold a conference call to discuss the results at 4:30 p.m. Eastern Time. Participants who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who want to join the audio-only
- GlobeNewswire
Harvard Bioscience Announces Second Quarter 2022 Financial Results
HOLLISTON, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter ended June 30, 2022. Jim Green, Chairman and CEO, said, "Our second quarter revenues were essentially flat compared to the prior year quarter as growth in our cellular/molecular product revenues were offset by reductions in pre-clinical revenues and an unfavorable foreign currency impact. Adjusted operating income for Q2 was lower th
- GlobeNewswire
Harvard Bioscience Schedules Second Quarter 2022 Earnings Conference Call for August 4, 2022 at 8:00 AM ET
HOLLISTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2022 before the market opens on August 4, 2022, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Participants who want to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number. Participants who want to join the audio-only webcas
